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Abstract 
 
 
The potential to improve pulmonary tuberculosis (PTB) treatment outcomes with 
adjunctive immunotherapies requires investigation. L-arginine and vitamin D have 
antimycobacterial properties which render them suitable candidates. Therefore the 
Arginine and Vitamin D Adjunctive therapy in Pulmonary TB (AVDAPT) trial 
evaluates these supplements in PTB. This large trial commenced in June 2008. The 
project is run in Timika, Papua Province, Indonesia by the International Health 
Division, Menzies School of Health Research (Darwin, Australia), the National 
Institute for Health Research and Development (Ministry of Health, Indonesia), and 
the Australian National University (Canberra).  
 
Aims of this thesis were to design and commence the AVDAPT study and examine 
baseline data. Among the tested hypotheses were that exhaled nitric oxide (FENO), an 
L-arginine-derived antimycobacterial immunological mediator, would be elevated in 
PTB compared with healthy controls (HC), and inversely related to disease severity; 
secondly, that significant relationships would exist between different measures of TB 
severity. 
 
Consenting, eligible adults with smear-positive PTB were enrolled at the Timika TB 
clinic according to the protocol. Assessments included sputum microscopy, culture 
and susceptibility, X-ray, weight, pulmonary function, FENO, 6-minute walk testing 
(6MWT) and quality of life (St George‘s Respiratory Questionnaire [SGRQ]). HC 
were enrolled for a single assessment. 
 
Results from 162 TB patients and 40 HC included: (1) findings pertaining to the trial 
(development / validation of outcome measures, and establishment of locally-relevant 
reference ranges for 6MWT and SGRQ); (2) findings pertaining to improved 
understanding of TB (demonstration of relationships between clinical, physiological, 
immunological [FENO] and functional measures of disease severity), and (3) 
investigation of TB drug-resistance and HIV rates. 
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A key finding was that FENO was not elevated in TB compared with HC and was 
lower still in worse disease. These findings suggest that an impaired ability to 
generate adequate NO (e.g. in L-arginine deficiency) might contribute to host inability 
to adequately contain TB or mitigate lung pathology. These findings support the 
rationale for conducting a trial of adjunctive L-arginine in TB.  
 
New relationships were identified between sputum smear grade, X-ray, weight, 
pulmonary function, 6MWT and SGRQ. Patients with more-severe malnutrition had 
worse pulmonary function; 6MWT was independent of lung function; SGRQ results 
accurately captured people‘s perceived quality of life, correlating significantly with 
symptoms, 6MWT and pulmonary function; and sputum bacillary grade was 
significantly related to radiological extent and weight, but not to other results. These 
findings support the use of a range of outcome measures in TB trials, to provide a 
comprehensive assessment of TB severity, rather than focusing on bacteriology alone. 
 
An x-ray severity score and a clinical outcome score were created, providing valuable 
tools for use in clinical trials. Interim analysis confirmed the safety of L-arginine and 
vitamin D adjunctive therapy. Multi-drug resistant TB rates remained low in new 
cases (2.0%), but HIV-TB co-infection rates rose significantly over 5 years, creating 
major challenges.  
 
This thesis provides the basis for continuation of the AVDAPT study, produces 
original findings relating to clinico-immunological aspects of PTB, and provides 
information of major local importance to help guide TB service provision in Timika.  
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Glossary 
 
6MWT   6 minute walk test 
6MWWD  6 minute weight.walk distance 
AE  Adverse event 
AVDAPT Arginine and Vitamin D Adjunctive therapy in pulmonary tuberculosis 
AFB  Acid-fast bacilli 
AIDS  Acquired immunodeficiency syndrome 
ANU  Australian National University  
BTA  Basil tahan asam (acid-fast bacilli) 
CI  Confidence interval 
Dinas  Dinas Kesehatan (District Health Authority) 
DOT  Directly Observed Treatment 
DOTS  Directly Observed Treatment, Short-course 
DSMC  Data and Safety Monitoring Committee 
E  Ethambutol 
FDC  Fixed-dose combination antituberculous therapy 
FENO  Fractional exhaled nitric oxide 
FEV1  Forced expiratory volume in 1 minute 
FKUI  Faculty of Microbiology, University of Indonesia  
GMP  Good Manufacturing Practice 
H  Isoniazid  
HIV  Human Immunodeficiency Virus 
IFN-γ  Interferon gamma 
IMVS  Institute for Medical & Veterinary Science  
MDR-TB Multi-drug resistant TB 
MGIT  Mycobacterium Growth Indicator Tube 
MIRU  Micro-satellite Interstitial Repetitive Unit  
MSHR  Menzies School of Health Research (Darwin, Australia) 
MTB  Mycobacterium tuberculosis 
NCEPH  National Centre for Epidemiology & Population Health (Australia) 
NHMRC National Health & Medical Research Council (Australia) 
NIHRD  National Institute of Health Research & Development (Indonesia) 
NiOX FLEX  Device for measurement of exhaled nitric oxide (non-portable)  
NiOX MINO Device for measurement of exhaled nitric oxide (portable) 
NO  Nitric oxide 
NOS  Nitric Oxide synthase 
NTP  National TB Control Program  
PTB  Pulmonary TB 
PT  Perseroan Terbatus (Proprietary Limited)  
Puskesmas    Pusat Kesehatan Masyarakat (Community Health Centre) 
R  Rifampicin 
RA  Research assistant 
RCT  Randomised, controlled trial 
RSMM  Rumah Sakit Mitra Mayarakat (Community hospital, Timika) 
RSUD  Rumah Sakit Umum Daerah (Regional General Hospital, Timika) 
S  Streptomycin 
SAE  Serious adverse events 
SGRQ  St George‟s Respiratory Questionnaire 
TB  Tuberculosis 
Th1  T helper cell Type 1 
TLR  Toll-like receptor 
TNF  Tumour necrosis factor 
UV  Ultraviolet 
VCT  Voluntary counselling and testing for HIV 
WHO  World Health Organization 
XDR-TB Extensively drug-resistant TB  
Z  Pyrazinamide  
 
Tables of contents 
ix 
 
 
 
Table of Contents 
 
AUTHOR‟S STATEMENT ........................................................................................................................ I 
ACKNOWLEDGEMENTS ...................................................................................................................... II 
ABSTRACT .............................................................................................................................................. VI 
GLOSSARY ........................................................................................................................................... VIII 
1 AIMS .................................................................................................................................................. 1 
1.1 BACKGROUND ................................................................................................................................ 1 
1.2 AIMS ............................................................................................................................................... 2 
2 INTRODUCTION I: TUBERCULOSIS ........................................................................................ 1 
3 INTRODUCTION II: ADJUNCTIVE TREATMENT IN TB ...................................................... 5 
3.1 WHY ARE NEW TREATMENT APPROACHES NEEDED? ....................................................................... 5 
3.2 ADJUNCTIVE THERAPIES .................................................................................................................. 8 
3.3 ARGININE AND VITAMIN D AS NOVEL POTENTIAL ADJUNCTIVE TREATMENTS IN TB ...................... 10 
4 INTRODUCTION III: NITRIC OXIDE AND ITS MEASUREMENT IN VIVO ................... 19 
4.1 NITRIC OXIDE PATHWAYS .............................................................................................................. 19 
4.2 EXHALED NITRIC OXIDE MEASUREMENT ....................................................................................... 20 
5 STUDY SETTING .......................................................................................................................... 26 
5.1 TIMIKA FIELD RESEARCH FACILITY ............................................................................................... 26 
5.2 TIMIKA TB CLINIC........................................................................................................................ 28 
5.3 OVERVIEW OF TIMIKA .................................................................................................................. 29 
5.4 CONDUCT OF MEDICAL RESEARCH IN PAPUA ............................................................................... 34 
5.5 CONCLUSION ................................................................................................................................ 34 
6 AVDAPT STUDY DESIGN AND METHODOLOGY ............................................................... 36 
6.1 BACKGROUND .............................................................................................................................. 36 
6.2 HYPOTHESES ................................................................................................................................ 37 
6.3 AIMS ............................................................................................................................................. 37 
6.4 METHODS ..................................................................................................................................... 38 
6.5 HEALTHY VOLUNTEER SUB-STUDY ................................................................................................ 65 
7 RESULTS I: BASELINE DATA IN STUDY PARTICIPANTS AND HEALTHY 
VOLUNTEERS ........................................................................................................................................ 67 
7.1 INTRODUCTION ............................................................................................................................. 67 
7.2 METHODS ..................................................................................................................................... 68 
7.3 RESULTS ....................................................................................................................................... 70 
7.4 DISCUSSION .................................................................................................................................. 85 
7.5 CONCLUSION ................................................................................................................................ 93 
8 RESULTS II: RELATIONSHIPS BETWEEN MICROBIOLOGICAL, CLINICAL AND 
FUNCTIONAL MEASURES OF TB SEVERITY ................................................................................ 94 
8.1 INTRODUCTION ............................................................................................................................. 94 
8.2 METHODS ..................................................................................................................................... 95 
8.3 RESULTS ....................................................................................................................................... 95 
8.4 DISCUSSION ................................................................................................................................ 100 
8.5 CONCLUSION .............................................................................................................................. 103 
9 RESULTS III: MEASURING TB RADIOLOGICAL SEVERITY ......................................... 104 
Tables of contents 
x 
10 RESULTS IV: LONGITUDINAL FOLLOW UP ...................................................................... 105 
10.1 INTRODUCTION ....................................................................................................................... 105 
10.2 METHODS ............................................................................................................................... 107 
10.3 RESULTS ................................................................................................................................. 110 
10.4 DISCUSSION ............................................................................................................................ 123 
10.5 CONCLUSION .......................................................................................................................... 129 
11 RESULTS V: EXHALED NITRIC OXIDE IN PULMONARY TB ........................................ 131 
11.1 INTRODUCTION ....................................................................................................................... 131 
11.2 METHODS ............................................................................................................................... 132 
11.3 RESULTS ................................................................................................................................. 134 
11.4 DISCUSSION ............................................................................................................................ 143 
11.5 CONCLUSIONS ......................................................................................................................... 150 
12 RESULTS VI: HIV-TB CO-INFECTION .................................................................................. 152 
12.1 INTRODUCTION ....................................................................................................................... 152 
12.2 METHODS ............................................................................................................................... 154 
12.3 RESULTS ................................................................................................................................. 155 
12.4 DISCUSSION ............................................................................................................................ 160 
12.5 CONCLUSION .......................................................................................................................... 163 
13 CONCLUSIONS AND FUTURE DIRECTIONS ...................................................................... 165 
13.1 CLINICAL FINDINGS ................................................................................................................ 166 
13.2 HIV-TB AND MDR-TB TRENDS............................................................................................. 168 
13.3 CONCLUSIONS FROM THE AVDAPT STUDY TO DATE ............................................................. 168 
14 REFERENCES .............................................................................................................................. 171 
15 APPENDICES ............................................................................................................................... 187 
15.1 STUDY INVESTIGATORS .......................................................................................................... 187 
15.2 GOOD CLINICAL PRACTICE CERTIFICATION ............................................................................ 189 
15.3 TRIAL REGISTRATION ............................................................................................................. 190 
15.4 AVDAPT INFORMATION AND CONSENT FORMS ..................................................................... 191 
15.5 AVDAPT DATA COLLECTION FORMS ..................................................................................... 195 
15.6 ST GEORGE‘S RESPIRATORY QUESTIONNAIRE ........................................................................ 205 
15.7 ARGIMAX CERTIFICATE OF ANALYSIS ..................................................................................... 207 
15.8 CALCIFEROL STRONG CERTIFICATE OF ANALYSIS ................................................................... 208 
15.9 SAFTEY REPORTING PROCESS ................................................................................................. 209 
15.10 SERIOUS ADVERSE EVENT REPORT FORM ................................................................................ 211 
15.11 HYPERCALCAEMIA MANAGEMENT GUIDELINE ........................................................................ 214 
15.12 EXAMPLE OF EPIDATA DATABASE ......................................................................................... 216 
15.13 HEALTHY VOLUNTEER INFORMATION & CONSENT FORM ...................................................... 217 
15.14 HEALTHY VOLUNTEER DATA COLLECTION FORM ................................................................... 219 
 
TABLES 
Table 2.1: Chronology of TB milestones ...................................................................................................... 1 
Table 4.1: Factors associated with abnormal exhaled nitric oxide ............................................................ 23 
Table 6.1: Follow-up schedule for AVDAPT study participants ................................................................ 51 
Table 6.2: Blood collection schedule for AVDAPT study participants ....................................................... 52 
Table 7.1: Baseline characteristics of AVDAPT study participants (TB patients) and healthy volunteers 72 
Table 7.2: Symptoms ................................................................................................................................... 74 
Table 7.3: Baseline clinical findings and haemoglobin .............................................................................. 75 
Table 7.4: Baseline laboratory and radiological findings .......................................................................... 79 
Table 7.5: Agreement in sputum AFB grade .............................................................................................. 81 
Table 8.1:Association between sputum smear grade at diagnosis and other measures of disease severity
 .................................................................................................................................................................... 96 
Table 8.2: Regression coefficients from univariate linear regression models examining associations 
between clinical and laboratory measures* ............................................................................................... 97 
Table 8.3: Correlation matrices showing correlation coefficients (top number) and p values (bottom 
number) for baseline clinical and laboratory measures* ........................................................................... 98 
Tables of contents 
xi 
Table 10.1: Composite clinical outcome score ........................................................................................ 108 
Table 10.2: Sputum MTB microscopy and culture results at baseline and 4 and 8 weeks ....................... 112 
Table 10.3: Predictors of sputum culture conversion, univariate analyses ............................................. 116 
Table 10.4: Six-month treatment outcome................................................................................................ 116 
Table 10.5: Composite clinical outcome score at 8 weeks (end of intensive treatment phase) and 24 weeks 
(end of treatment) ..................................................................................................................................... 117 
Table 10.6: Correlations between outcome scores and percentage change in other measures ............... 118 
Table 10.7: Serious adverse events (SAE) ................................................................................................ 121 
Table 10.8: Number of study participants with hypercalcaemia .............................................................. 122 
Table 10.9: Summary of findings of the interim analysis ......................................................................... 123 
Table 11.1: Correlation between FENO measures .................................................................................... 134 
Table 11.2: Corrections applied to exhaled nitric oxide readings obtained from the NiOX MINO portable 
analyser .................................................................................................................................................... 137 
Table 11.3: Characteristics and FENO in healthy volunteers and TB patients at enrolment .................... 138 
Table 11.4: Summary of salient findings from the present study and previous investigations of exhaled 
nitric oxide in tuberculosis ....................................................................................................................... 149 
Table 12.1: Characteristics of 138 study participants with known HIV status ........................................ 156 
Table ‎12.2: Treatment outcome in HIV positive and HIVnegative study participants ............................. 159 
Table 12.3: TB-HIV coinfection management .......................................................................................... 160 
 
FIGURES  
FIGURE 1: NIHRD-MSHR Timika research staff outside the research buidling ........................................ v 
Figure 4.1: NiOX FLEX ............................................................................................................................. 22 
Figure 4.2: NiOX MINO ............................................................................................................................ 23 
Figure 5.1: Map of Indonesia and Northern Australia showing Timika (Papua Province) ....................... 26 
Figure 5.2: Timika community hospital (Rumah Sakit Mitra Masyarakat) ............................................... 27 
Figure 5.3: NIHRD-MSHR Timika research staff and visitors in the research buidling ........................... 28 
Figure 5.4: Timika TB clinic and staff ....................................................................................................... 29 
Figure 5.5: Mimika district map ................................................................................................................ 30 
Figure 5.6: HIV education banner near RSMM hospital ........................................................................... 34 
Figure 5.7: Images of Timika ..................................................................................................................... 35 
Figure 6.1: Diagrammatic representation of AVDAPT trial and related studies ...................................... 39 
Figure 6.2: Consent booklet ....................................................................................................................... 41 
Figure 6.3: Enrolment procedure .............................................................................................................. 44 
Figure 6.4: Sample stickers applied to study medications ......................................................................... 46 
Figure 6.5: Spirometer calibration using 3 litre syringe ........................................................................... 48 
Figure 6.6: Mycobacterial growth indicator tubes (MGIT) ....................................................................... 51 
Figure 6.7: Sample processing at the NIHRD-MSHR research facility ..................................................... 53 
Figure 7.1: Eligibility screening and enrolment of AVDAPT study participants ....................................... 71 
Figure 7.2: Smoking rates in male and female AVDAPT study participants and healthy volunteers* ...... 73 
Figure 7.3: Educational attainment in Papuan and Non-Papuan study  participants* ............................. 73 
Figure 7.4: Employment status in Papuan and Non-Papuan study participants ....................................... 74 
Figure 7.5: Symptoms reported among AVDAPT study participants at TB diagnosis ............................... 76 
Figure 7.6: Number of symptoms reported at the time of TB diagnosis in men and women ...................... 76 
Figure 7.7: Nutritional status in AVDAPT study participants ................................................................... 77 
Figure 7.8: Haemoglobin according to sex, ethnicity, HIV status and in healthy volunteers versus TB 
patients overall ........................................................................................................................................... 80 
Figure 7.9: Educational attainment in healthy volunteers and TB patients* ............................................. 82 
Figure 7.10: Telephone ownership in TB patients and healthy volunteers ................................................ 82 
Figure 7.11: Employment status in TB patients and healthy volunteers .................................................... 83 
Figure 7.12: BMI in healthy volunteers and AVDAPT study participants ................................................. 83 
Figure 7.13: Six minute walk distances in healthy volunteers and AVDAPT study participants* ............. 84 
Figure‎7.14:‎St‎George’s‎respiratory‎questionnaire‎total‎score‎in‎healthy‎volunteers‎and‎AVDAPT‎study‎
participants* .............................................................................................................................................. 85 
Figure 8.1: Relationship between smear grade at TB diagnosis and CXR score and weight .................... 96 
Figure 8.2: Relationships between lung function impairment and weight, haemoglobin, illness duration 
and quality of life total score (SGRQ) ........................................................................................................ 99 
Figure 8.3: Relationship between number of reported symptoms and illness duration and quality of life 
(SGRQ) score ........................................................................................................................................... 100 
Figure 8.4: Illness duration in relation to educational attainment .......................................................... 100 
Figure 10.1: Participant follow up profile ............................................................................................... 110 
Tables of contents 
xii 
Figure 10.2: Microscopy and culture results at enrolment, and 4 and 8 weeks in participants followed for 
8 weeks ...................................................................................................................................................... 112 
Figure 10.3: Kaplan-Meier survival curve showing probability of sputum smear conversion by ethnicity
 .................................................................................................................................................................. 114 
Figure 10.4: Kaplan-Meier survival curve showing probability of sputum smear conversion by HIV status
 .................................................................................................................................................................. 114 
Figure 10.5: Kaplan-Meier survival curve showing probability of sputum smear conversion by cavitary 
disease status ............................................................................................................................................ 115 
Figure 10.6: Kaplan-Meier survival curve showing probability of sputum smear conversion by baseline 
sputum AFB grade .................................................................................................................................... 115 
Figure 10.7: Histograms demonstrating distributions of composite clinical outcome scores at 8 and 24 
weeks ......................................................................................................................................................... 118 
Figure 10.8: Non-serious adverse events experienced by AVDAPT study participants ........................... 120 
Figure 10.9: Serial calcium readings in a representative individual receiving TB treatment and study 
medications ............................................................................................................................................... 122 
Figure 10.10: Ionised calcium (mean indicated by bar and range) by week in AVDAPT study participants
 .................................................................................................................................................................. 122 
Figure 11.1: Bland-Altman plot: repeated exhaled nitric oxide measures on single analyser ................. 135 
Figure 11.2: Bland-Altman plot: paired exhaled nitric oxide measures on 2 analysers .......................... 135 
Figure 11.3: Bland-Altman plot: paired exhaled nitric oxide measures on the NiOX MINO (portable 
analyser)‎and‎NiOX‎FLEX‎(‘gold‎standard’) ........................................................................................... 136 
Figure 11.4: Relationship between exhaled nitric oxide measures on the Niox Mino and Niox Flex ...... 136 
Figure 11.5: Exhaled nitric oxide in healthy volunteers and TB patients at week 0 and during TB 
treatment ................................................................................................................................................... 140 
Figure 11.6: Exhaled nitric oxide according to sex in TB patients at week 0 .......................................... 141 
Figure 11.7: Exhaled nitric oxide according to weight in TB patients at week 0 ..................................... 141 
Figure 11.8: Correlations between change in FENO and clinical outcome score at weeks 8 and 24 ....... 142 
Figure 12.1: Rates of HIV-TB co-infection among study participants ..................................................... 157 
Figure 12.2: HIV-TB co-infection rates in Timika in 2003-4 compared with 2008-9 .............................. 158 
Figure 12.3: Meeting between AVDAPT research personell and local HIV care providers .................... 164 
 
BOXES 
Box 3.1: Actions of Vitamin D .................................................................................................................... 13 
Box 4.1: Principles of exhaled nitric oxide measurement ........................................................................... 21 
Box 5.1: Approvals required for conducting medical research in Papua, Indonesia ................................. 35 
Box 6.1: Explanation regarding planned off-shore laboratory analyses .................................................... 55 
Box 7.1: Definitions .................................................................................................................................... 69 
Box 7.2: Locally-relevant reference ranges for 6-minute walk testing ....................................................... 85 
Box 10.1: AVDAPT study primary outcome measures ............................................................................. 106 
 
PUBLISHED AND SUBMITTED MANUSCRIPTS 
Manuscript 1: Ralph AP, Anstey NM, Kelly PM. Tuberculosis into the 2010s: is the glass half full? Clin 
Infect Dis 2009;49(4):574-83. ...................................................................................................................... 3 
Manuscript 2: Ralph A, Kelly P, Krause V. What's new in TB? Australian Family Physician 2009; 
38(8):578-585. .............................................................................................................................................. 4 
Manuscript 3: Ralph AP, Kelly PM, Anstey NM. L-arginine and vitamin D: novel adjunctive 
immunotherapies in tuberculosis. Trends Microbiol 2008;16(7):336-44. .................................................. 15 
Manuscript 4: Ralph AP, Ardian M, Wiguna A, Maguire GP, Becker NG, Drogumuller D, Wilks MJ, 
Waramori G, Tjitra E, Sandjaja, Kenangalem E, Pontororing GJ, Anstey NA, Kelly PM. A simple, valid, 
numerical score for grading chest X-ray severity in adult smear positive pulmonary tuberculosis. 
Accepted, Thorax, July 2010..................................................................................................................... 104 
